{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:14:28Z","timestamp":1769260468521,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00430-019-00625-6","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T04:55:47Z","timestamp":1563425747000},"page":"835-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["HTLV-1-infected asymptomatic carriers compared to HAM\/TSP patients over-express the apoptosis- and cytotoxicity-related molecules"],"prefix":"10.1007","volume":"208","author":[{"given":"Asadollah","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahare","family":"Fazeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohreh","family":"Poursina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farahnaz","family":"Tehranian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veda","family":"Vakili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Boostani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houshang","family":"Rafatpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"51","key":"625_CR1","doi-asserted-by":"publisher","first-page":"15525","DOI":"10.1073\/pnas.1521629112","volume":"112","author":"JM Coffin","year":"2015","unstructured":"Coffin JM (2015) The discovery of HTLV-1, the first pathogenic human retrovirus. Proc Natl Acad Sci USA 112(51):15525\u201315529","journal-title":"Proc Natl Acad Sci USA"},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O (2012) Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3:388","journal-title":"Front Microbiol"},{"issue":"3","key":"625_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcv.2011.07.004","volume":"52","author":"H Rafatpanah","year":"2011","unstructured":"Rafatpanah H et al (2011) High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 52(3):172\u2013176","journal-title":"J Clin Virol"},{"issue":"3","key":"625_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1128\/CMR.00063-09","volume":"23","author":"DU Goncalves","year":"2010","unstructured":"Goncalves DU et al (2010) Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 23(3):577\u2013589","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"625_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11481-010-9216-9","volume":"5","author":"E Matsuura","year":"2010","unstructured":"Matsuura E, Yamano Y, Jacobson S (2010) Neuroimmunity of HTLV-I infection. J Neuroimmune Pharmacol 5(3):310\u2013325","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"625_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/13550289809114225","volume":"4","author":"M Nagai","year":"1998","unstructured":"Nagai M et al (1998) Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM\/TSP. J Neurovirol 4(6):586\u2013593","journal-title":"J Neurovirol"},{"issue":"1","key":"625_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/blood.V99.1.88","volume":"99","author":"Y Yamano","year":"2002","unstructured":"Yamano Y et al (2002) Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM\/TSP). Blood 99(1):88\u201394","journal-title":"Blood"},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.biopha.2016.11.034","volume":"85","author":"M Karimi","year":"2017","unstructured":"Karimi M et al (2017) Role of the HTLV-1 viral factors in the induction of apoptosis. Biomed Pharmacother 85:334\u2013347","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"625_CR9","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.4049\/jimmunol.0900069","volume":"182","author":"T Kattan","year":"2009","unstructured":"Kattan T et al (2009) The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol 182(9):5723\u20135729","journal-title":"J Immunol"},{"issue":"9","key":"625_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2015-04-641118","volume":"126","author":"K Sugata","year":"2015","unstructured":"Sugata K et al (2015) Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood 126(9):1095\u20131105","journal-title":"Blood"},{"issue":"8","key":"625_CR11","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.4049\/jimmunol.173.8.5121","volume":"173","author":"AM Vine","year":"2004","unstructured":"Vine AM et al (2004) The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol 173(8):5121\u20135129","journal-title":"J Immunol"},{"key":"625_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.biopha.2016.11.050","volume":"85","author":"A Mohammadi","year":"2017","unstructured":"Mohammadi A et al (2017) Modulatory effects of curcumin on apoptosis and cytotoxicity-related molecules in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients. Biomed Pharmacother 85:457\u2013462","journal-title":"Biomed Pharmacother"},{"issue":"2\u20133","key":"625_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000490058","volume":"18","author":"SH Mozhgani","year":"2018","unstructured":"Mozhgani SH et al (2018) Interferon lambda family along with HTLV-1 proviral load, tax, and HBZ implicated in the pathogenesis of myelopathy\/tropical spastic paraparesis. Neurodegener Dis 18(2\u20133):150\u2013155","journal-title":"Neurodegener Dis"},{"issue":"2","key":"625_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/vim.2018.0048","volume":"32","author":"N Yaghouti","year":"2019","unstructured":"Yaghouti N et al (2019) Role of receptors for advanced glycation end products and high-mobility group box 1 in the outcome of human T cell lymphotropic type 1 infection. Viral Immunol 32(2):89\u201394","journal-title":"Viral Immunol"},{"issue":"6","key":"625_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nri819","volume":"2","author":"M Barry","year":"2002","unstructured":"Barry M, Bleackley RC (2002) Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2(6):401\u2013409","journal-title":"Nat Rev Immunol"},{"key":"625_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.coviro.2015.10.008","volume":"16","author":"SN Waggoner","year":"2016","unstructured":"Waggoner SN et al (2016) Roles of natural killer cells in antiviral immunity. Curr Opin Virol 16:15\u201323","journal-title":"Curr Opin Virol"},{"issue":"11","key":"625_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/ni1102-1013","volume":"3","author":"CA Benedict","year":"2002","unstructured":"Benedict CA, Norris PS, Ware CF (2002) To kill or be killed: viral evasion of apoptosis. Nat Immunol 3(11):1013\u20131018","journal-title":"Nat Immunol"},{"issue":"8","key":"625_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/v3081320","volume":"3","author":"A Abrams","year":"2011","unstructured":"Abrams A, Akahata Y, Jacobson S (2011) The Prevalence and Significance of HTLV-I\/II Seroindeterminate Western Blot Patterns. Viruses 3(8):1320","journal-title":"Viruses"},{"issue":"6","key":"625_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1046\/j.1537-2995.2002.00114.x","volume":"42","author":"R Thorstensson","year":"2002","unstructured":"Thorstensson R, Albert J, Andersson S (2002) Strategies for diagnosis of HTLV-I and -II. Transfusion 42(6):780\u2013791","journal-title":"Transfusion"},{"issue":"7","key":"625_CR20","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/eji.200323977","volume":"33","author":"K Ogawa","year":"2003","unstructured":"Ogawa K et al (2003) Granulysin in human serum as a marker of cell-mediated immunity. Eur J Immunol 33(7):1925\u20131933","journal-title":"Eur J Immunol"},{"issue":"1\u20132","key":"625_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2012.05.004","volume":"250","author":"H Rafatpanah","year":"2012","unstructured":"Rafatpanah H et al (2012) The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 250(1\u20132):87\u201393","journal-title":"J Neuroimmunol"},{"issue":"10","key":"625_CR22","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00018-010-0289-7","volume":"67","author":"R Weinlich","year":"2010","unstructured":"Weinlich R, Brunner T, Amarante-Mendes GP (2010) Control of death receptor ligand activity by posttranslational modifications. Cell Mol Life Sci 67(10):1631\u20131642","journal-title":"Cell Mol Life Sci"},{"key":"625_CR23","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3389\/fmicb.2017.02563","volume":"8","author":"Y Enose-Akahata","year":"2017","unstructured":"Enose-Akahata Y, Vellucci A, Jacobson S (2017) Role of HTLV-1 tax and HBZ in the pathogenesis of HAM\/TSP. Front Microbiol 8:2563","journal-title":"Front Microbiol"},{"key":"625_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-4690-6-19","volume":"6","author":"M Saito","year":"2009","unstructured":"Saito M et al (2009) In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). Retrovirology 6:19","journal-title":"Retrovirology"},{"issue":"10","key":"625_CR25","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00018-016-2164-7","volume":"73","author":"V Tisato","year":"2016","unstructured":"Tisato V et al (2016) Clinical perspectives of TRAIL: insights into central nervous system disorders. Cell Mol Life Sci 73(10):2017\u20132027","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"625_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00109-009-0484-x","volume":"87","author":"O Hoffmann","year":"2009","unstructured":"Hoffmann O, Zipp F, Weber JR (2009) Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation. J Mol Med (Berl) 87(8):753\u2013763","journal-title":"J Mol Med (Berl)"},{"issue":"12","key":"625_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.tins.2011.09.002","volume":"34","author":"C Mc Guire","year":"2011","unstructured":"Mc Guire C, Beyaert R, van Loo G (2011) Death receptor signalling in central nervous system inflammation and demyelination. Trends Neurosci 34(12):619\u2013628","journal-title":"Trends Neurosci"},{"issue":"6\u20137","key":"625_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ejcb.2010.10.006","volume":"90","author":"M Lettau","year":"2011","unstructured":"Lettau M et al (2011) Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol 90(6\u20137):456\u2013466","journal-title":"Eur J Cell Biol"},{"issue":"2","key":"625_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.pharmthera.2013.06.009","volume":"140","author":"T Sessler","year":"2013","unstructured":"Sessler T et al (2013) Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. Pharmacol Ther 140(2):186\u2013199","journal-title":"Pharmacol Ther"},{"issue":"4","key":"625_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2174\/156652409788167078","volume":"9","author":"N Cummins","year":"2009","unstructured":"Cummins N, Badley A (2009) The TRAIL to viral pathogenesis: the good, the bad and the ugly. Curr Mol Med 9(4):495\u2013505","journal-title":"Curr Mol Med"},{"issue":"7","key":"625_CR31","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.4049\/jimmunol.181.7.4918","volume":"181","author":"EL Brincks","year":"2008","unstructured":"Brincks EL et al (2008) CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol 181(7):4918\u20134925","journal-title":"J Immunol"},{"issue":"1\u20132","key":"625_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0165-5728(97)00012-X","volume":"75","author":"A Inoue","year":"1997","unstructured":"Inoue A et al (1997) Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Neuroimmunol 75(1\u20132):141\u2013146","journal-title":"J Neuroimmunol"},{"issue":"9","key":"625_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1089\/107999099313208","volume":"19","author":"T Sakai","year":"1999","unstructured":"Sakai T et al (1999) Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus Type I-associated myelopathy. J Interferon Cytokine Res 19(9):999\u20131004","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"625_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0165-5728(99)00095-8","volume":"98","author":"M Saito","year":"1999","unstructured":"Saito M et al (1999) Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy\/tropical spastic paraparesis patients. J Neuroimmunol 98(2):221\u2013226","journal-title":"J Neuroimmunol"},{"issue":"3","key":"625_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.rmed.2003.09.015","volume":"98","author":"N Sakamoto","year":"2004","unstructured":"Sakamoto N et al (2004) Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1. Respir Med 98(3):213\u2013219","journal-title":"Respir Med"},{"issue":"2","key":"625_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0165-5728(98)00147-7","volume":"90","author":"N Kawahigashi","year":"1998","unstructured":"Kawahigashi N et al (1998) Predominant expression of Fas ligand mRNA in CD8\u2009+\u2009T lymphocytes in patients with HTLV-1 associated myelopathy. J Neuroimmunol 90(2):199\u2013206","journal-title":"J Neuroimmunol"},{"issue":"4","key":"625_CR37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00401-001-0478-4","volume":"103","author":"F Umehara","year":"2002","unstructured":"Umehara F et al (2002) Involvement of Fas\/Fas ligand system in the spinal cords of HTLV-I-associated myelopathy. Acta Neuropathol 103(4):384\u2013390","journal-title":"Acta Neuropathol"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-019-00625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00430-019-00625-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-019-00625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:16:09Z","timestamp":1594941369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00430-019-00625-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s00430-019-00625-6","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}